

Germline mutation in *POLR2A*: a heterogeneous, multi-systemic developmental disorder characterized by transcriptional dysregulation

Adam W. Hansen,^{1,2,*} Payal Arora,³ Michael M. Khayat,^{1,2} Leah J. Smith,⁴ Andrea M. Lewis,² Linda Z. Rossetti,² Joy Jayaseelan,¹ Ingrid Cristian,⁵ Devon Haynes,⁵ Stephanie DiTroia,⁶ Naomi Meeks,⁷ Mauricio R. Delgado,^{8,9} Jill A. Rosenfeld,^{2,10} Lynn Pais,⁶ Susan M. White,^{11,12} Qingchang Meng,¹ Davut Pehlivan,^{2,13} Pengfei Liu,^{2,10} Marie-Claude Gingras,^{1,2,14} Michael F. Wangler,^{2,15} Donna M. Muzny,^{1,2} James R. Lupski,^{1,2,16,17} Craig D. Kaplan,^{3,*} and Richard A. Gibbs^{1,2}

Summary

De novo germline variation in *POLR2A* was recently reported to associate with a neurodevelopmental disorder. We report twelve individuals harboring putatively pathogenic *de novo* or inherited variants in *POLR2A*, detail their phenotypes, and map all known variants to the domain structure of *POLR2A* and crystal structure of RNA polymerase II. Affected individuals were ascertained from a local data lake, pediatric genetics clinic, and an online community of families of affected individuals. These include six affected by *de novo* missense variants (including one previously reported individual), four clinical laboratory samples affected by missense variation with unknown inheritance—with yeast functional assays further supporting altered function—one affected by a *de novo* in-frame deletion, and one affected by a C-terminal frameshift variant inherited from a largely asymptomatic mother. Recurrently observed phenotypes include ataxia, joint hypermobility, short stature, skin abnormalities, congenital cardiac abnormalities, immune system abnormalities, hip dysplasia, and short Achilles tendons. We report a significantly higher occurrence of epilepsy (8/12, 66.7%) than previously reported (3/15, 20%) (p value = 0.014196; chi-square test) and a lower occurrence of hypotonia (8/12, 66.7%) than previously reported (14/15, 93.3%) (p value = 0.076309). *POLR2A*-related developmental disorders likely represent a spectrum of related, multi-systemic developmental disorders, driven by distinct mechanisms, converging at a single locus.

Introduction

The human enzyme DNA-directed RNA polymerase II (EC 2.7.7.6) transcribes all nuclearly encoded messenger RNA (mRNA). It is a large enzyme composed of twelve subunits, the largest of which—the 220-kDa subunit A—is encoded by *POLR2A* (MIM: 180660). *POLR2A* contains essential domains of the RNA polymerase II enzyme, including the catalytic core and a C-terminal heptapeptide repeat, the differential phosphorylation of which is critical for regulating transcriptional dynamics.^{1,2} Numerous structural and mutational studies in various systems have been conducted, revealing a spectrum of genetic variants differentially impacting distinct dimensions of transcription (i.e., initiation, elongation, etc.).^{3,4} Indeed, the function of RNA polymerase II has been extensively studied for decades.

Despite its centrality within the central dogma of molecular biology and its extensive study over decades, *POLR2A*

was not implicated in human disease until 2016, when Clark et al.⁵ reported multiple distinct, recurrent somatic mutations in the gene as causative for a clinically unique subset of meningiomas. Very recently the first report of pathogenic germline mutations in *POLR2A* was published, describing a phenotypically heterogeneous neurodevelopmental syndrome with hypotonia (MIM: 618603).⁶ Here, we report additional clinical and molecular evidence strengthening the case for *POLR2A* dysfunction as a multi-systemic, phenotypically heterogeneous Mendelian disorder.

Material and methods

DNA sequencing and genotyping

For individuals 1, 6, and 8–13, DNA capture and sequencing of exomes was carried out as previously described by Hansen et al.⁷ at either the Baylor Genetics (BG) laboratories or at the Baylor

¹Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA; ²Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; ³Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA, USA; ⁴Department of Biochemistry and Biophysics, Texas A&M University, TX, USA; ⁵Division of Genetics, Arnold Palmer Hospital for Children, Orlando Health, Orlando, FL, USA; ⁶Broad Center for Mendelian Genomics and Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA; ⁷Departments of Pediatrics and Genetics, University of Colorado School of Medicine, Aurora, CO, USA; ⁸Texas Scottish Rite Hospital for Children, Dallas, TX, USA; ⁹Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA; ¹⁰Baylor Genetics Laboratories, Houston, TX, USA; ¹¹Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Parkville 3052, VIC, Australia; ¹²Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia; ¹³Section of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; ¹⁴Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA; ¹⁵Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA; ¹⁶Texas Children's Hospital, Houston, TX, USA; ¹⁷Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

*Correspondence: awhphd@gmail.com (A.W.H.), craig.kaplan@pitt.edu (C.D.K.)

<https://doi.org/10.1016/j.xhgg.2020.100014>.

© 2020 The Authors. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



College of Medicine Human Genome Sequencing Center (HGSC). Sequencing and analysis for individuals 2 (genome sequencing) and 5 (exome sequencing [ES]) were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG). ES and analysis for individuals 3, 4, and 7 was performed at other commercial clinical laboratories. Chromosomal microarray analysis (CMA) for individual 8 was performed at BG. CMA for individuals 1–8, 10, and 12 were performed at other commercial clinical laboratories. It is unknown whether CMA was performed for individuals 9 and 11.

NGS analysis

Initially, a local data lake containing ES data for approximately 20,000 individuals with suspected Mendelian disorders (Hadoop ARchitecture Lake of Exomes [HARLEE]) was utilized to discover *POLR2A* as a candidate Mendelian disease-associating gene. Within this dataset, fastq files were aligned to hg19, and variants were called with Atlas2 (v1.4.3) and annotated with VEP.⁷ High-quality ultra-rare (MAF < 1/10,000) variants observed in individuals within HARLEE were prioritized. This analysis resulted in the discovery of ultra-rare, potentially pathogenic *POLR2A* variants in individuals 1, 6, and 8–13. Individuals 2–5 and 7 were ascertained for this study after the initial published discovery of a *POLR2A*-related developmental disorder, with analysis conducted by the Broad CMG or other commercial clinical laboratories.⁶

For all individuals, region-specific intolerance to missense variants is calculated with the Missense Tolerance Ratio (MTR) score,⁸ with scores < 1.0 indicating a lower-than-expected ratio of missense to synonymous variants in the ExAC dataset⁹ for the 31-bp window surrounding an amino acid residue. Estimates of residue-level conservation were obtained from GERP++¹⁰ via the UCSC Genome Browser.¹¹

Phenotyping

Phenotyping is described in the [Supplemental material and methods](#), with all phenotypes summarized in [Table 1](#).

Structural domains and alignment

POLR2A structural domains were derived from the yeast RNA polymerase II (Pol II) crystal structure, which shares a remarkably high level of conservation with *POLR2A*.³ Human *POLR2A* domain coordinates were derived by alignment as performed with MAFFT FFT-NS-2 (v7.305b).¹²

Functional evaluation of variants in yeast

Thirteen ultra-rare variants in *POLR2A* were identified in clinical samples at the time the yeast experiments were initiated. Yeast studies were conducted in the yeast ortholog of *POLR2A*, *RPO21* (generally referred to as *RPB1*), and are summarized in [Table 2](#). Detailed experimental methods are described in the [Supplemental material and methods](#).

Ethics statement

Data for individuals 1–8 were collected after written informed consent in conjunction with the Baylor Hopkins Center for Mendelian Genomics (CMG) (H-29697) study with approval by the institutional review board at Baylor College of Medicine. Other clinical samples (individuals 9–12) were from the Baylor College of Medicine clinical testing laboratories, now incorporated as BG; these data were studied in aggregate for the purpose of improving the diagnostic assay, under protocol H-41191. The procedures fol-

lowed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national), and proper informed consent was obtained.

Results

Utilizing the HARLEE data lake,⁷ a total of seven clinical exomes were originally identified with ultra-rare (MAF ≤ 1/10,000) suspected pathogenic variants in *POLR2A*. Attempts were made to contact all individuals and recruit to a research protocol (see [Material and methods](#)). After the initial report of *de novo* variation in *POLR2A* causing a Mendelian disorder,⁶ five additional individuals were subsequently identified through the genetics clinic at Texas Children's Hospital and a social media-based support group for families of individuals diagnosed with pathogenic variants in *POLR2A* ([Table 1](#)), including one previously published individual for whom amended and additional phenotypic information is provided (individual 7; Haijes et al.,⁶ individual 15). The family of individual 7 reports that she is positive for a few phenotypes previously reported as negative: feeding difficulty/failure to thrive, decreased endurance, and decreased fetal movement. Phenotypic data from clinical samples detected in HARLEE for individuals without research consent are reported in aggregate, in accordance with institutional review board (IRB)-approved protocols (see [Ethics statement](#)).

Clinical ES or genome sequencing revealed no other genetic diagnosis for any of these individuals. CMA reportedly did not reveal any findings for individuals 1–8 and 12. It is unknown whether CMA was performed for individuals 9 and 11. CMA for individual 10 reportedly identified a variant of uncertain significance (VUS) gain in Xp22.13. Thus, in total, twelve individuals with ultra-rare, putatively pathogenic variants in *POLR2A* are reported. Pathogenicity for all of these variants is supported by the extreme degree of constraint for missense (missense intolerance Z score = 8.59) and loss-of-function (pLI = 1.0) variants observed in healthy individuals from the ExAC dataset.⁹ All variants occur at highly conserved residues (as indicated by a GERP++ score ≥ 2.0), in regions further constrained for missense variation in the ExAC dataset ([Table 1](#)).^{8,10} Of these twelve individuals, there are ten affected by missense variants (including one previously published individual and two individuals affected by the same variant). We also report one individual affected by an in-frame deletion and one family affected by a C-terminal frameshift variant. Variants are distributed throughout the length of the protein product, with no obvious association between severity of phenotype and affected protein domain ([Figure 1](#)). We report one variant located within the Clamp core domain, two variants within the Clamp head, one variant within the Dock, three variants within the Cleft, one variant within the Trigger loop, one variant within the Jaw (observed in two individuals), and one

Table 1. Variant information and phenotypes of individuals with ultra-rare POLR2A variants

Individual ID	1	2	3	4	5	6	7 (Hajjes et al. ⁶ individual 15)	8	9	10	11	12	Summary	
Consented to sharing of individual-level phenotypes?	yes	yes	yes	yes	yes	yes	yes	yes	yes	no	no	no	no	NA
Sex	F	M	M	M	F	F	F	F	F	M	F	M	M	NA
Age (in years, at requisition or most recent phenotyping)	0.32	4	3.5	10	21	6.75	11	14	1.13	16.12	1.49	4.36	NA	
Molecular														
Previous/additional Molecular Diagnosis	unsolved	unsolved	unsolved	unsolved	unsolved	unsolved	mitochondrial complex IV deficiency indicated via skeletal muscle enzyme analysis; mtDNA sequencing was negative	unsolved	unsolved	unsolved	unsolved	unsolved	unsolved	NA
Chromosome	17	17	17	17	17	17	17	17	17	17	17	17	17	NA
Position	7401503	7411610	7411736	7412890	7412890	7415280	7416391	7417020	7388166	7399625	7399813	7411604	NA	
Genomic variant	GACCTTC>G	C>T	C>T	A>G	A>G	G>A	G>A	CCA>C	C>G	G>A	C>T	C>T	NA	
cDNA variant	c.1314_1319del	c.3281C>T	c.3407C>T	c.3752A>G	c.3752A>G	c.4252G>A	c.4808G>A	c.5440_5441del	c.83C>G	c.323G>A	c.418C>T	c.3275C>T	NA	
Amino acid change	p.Leu438_His439del	p.Ser1094Phe	p.Thr1136Ile	p.Asn1251Ser	p.Asn1251Ser	p.Gly1418Arg	p.Arg1603His	p.Gln1814_Valfs99ter	p.Pro28Arg	p.Arg108His	p.Arg140Trp	p.Ala1092Val	NA	
GERP++ score (conservation)	mean = 4.64 (0.89–5.6; SD = 1.9; 6 bases)	5.36	5.23	5.11	5.11	5.06	3.93	mean = 1.68 (–8.25–4.13; SD = 3.06; 476 bases)	5.82	5.57	5.57	5.36	NA	
MTR score (31 bp) (missense constraint)	mean = 0.675 (0.637–0.678; 2 amino acids)	0.477	0.172	0.516	0.516	0.301	1.031	mean = 0.7 (0.448–0.968; SD = 0.131; 158 amino acids)	0.598	0.649	0.673	0.528	NA	
Zygosity	het	het	het	het	het	het	het	het	het	het	het	het	NA	
<i>De novo</i> in proband?	yes	yes	yes	yes	yes	yes	yes	no; inherited from mother with mild difficulty learning	?	?	?	?	NA	
Yeast variant phenotype	transcription defect (weak) (yeast Ile424Δ corresponds to human p.Leu438del)	?	?	?	?	transcription defect (slight)	?	?	protein defect (strong)	protein defect (weak)	protein defect (strong)	transcription defect (weak)	NA	

(Continued on next page)

Table 1. Continued													
Individual ID	1	2	3	4	5	6	7 (Hajjes et al.⁶ individual 15)	8	9	10	11	12	Summary
Phenotypes													
Short stature (HP:0004322)	+	-	-	-	-	-	-	5th percentile	-	-	-	3/4	5/12
Head and neck													
Dysmorphic features (HP:0001999)	+	high anterior hairline; mild downslanting palpebral fissures; strabismus	high anterior hairline; epicanthus; downslanting palpebral fissures; long lateral palpebral fissures; tented upper lip vermilion; prominent ears	prominent supraorbital ridges; high posterior hairline; upslanted palpebral fissures; fair complexion; deeply set eyes; large ear lobes; high palate	prominent supraorbital ridges; high posterior hairline; upslanted palpebral fissures; fair complexion; deeply set eyes; strabismus (when tired)	broad forehead; bilateral epicanthus; prominent supraorbital ridges; fair complexion; deeply set eyes; strabismus (when tired)	-	prominent ears; thin upper lip vermilion; smooth philtrum	NP	-	-	3/4	9/12
Abnormal brain MRI (HP:0012443)	polymicrogyria (HP:0002126), ventriculomegaly (HP:0002119), hydrocephalus (HP:0000238), hypomyelination (HP:0006808)	Rathke cleft cyst	-	thin corpus callosum (HP:0002079), mild pontine and anterior vermian hypoplasia (HP:0012110, HP:0007068), enlargement of the fourth ventricle (HP:0002198), delayed myelination (HP:0012448)	prominent third and lateral ventricles at 1 year old (HP:0007082, HP:0006956)	-	thin corpus callosum (HP:0002079), ventriculomegaly (HP:0002119), 7 mm cyst in temporal parietal junction, bilateral loss of white matter (HP:0012429)	polymicrogyria involving large portions of left cerebral hemisphere including perisylvian region and portions of the left frontal, parietal, and temporal lobes (HP:0002126); left cerebral atrophy (HP:0002059); small enhancing developmental venous anomaly at right parieto-occipital junction (HP:0012481)	-	-	-	1/4	7/12
Microcephaly/macrocephaly	NP	-	-	significant microcephaly (<2 percentile)	-	-	microcephaly	-	-	-	-	macrocephaly 1/4	3/12
Visual impairment (HP:0000505)	NP	-	astigmatism, both eyes	bilateral elongation of ocular globes noted on MRI	-	cortical	irregular astigmatism, both eyes	wears glasses since age 2 years, no astigmatism reported	-	-	-	NP	5/12
Hearing impairment (HP:0000365)	NP	-	-	-	-	sensorineural	-	right-side hearing deficit attributed to hemiplegia	-	-	-	NP	2/12
Headache (HP:0002315)	NP	-	-	reported by parents; cannot confirm as individual is non-verbal	-	-	reported by parents; cannot confirm as individual is non-verbal	daily severe headaches	-	-	-	NP	1/10

(Continued on next page)

Table 1. Continued

Individual ID	1	2	3	4	5	6	7 (Haijes et al. individual 15)	8	9	10	11	12	Summary
Central nervous system													
Developmental delay (HP:0012758)	+	+	+	+	speech and motor (HP:0000750, HP:0001270)	+	+	speech and motor (HP:0000750, HP:0001270)			4/4		12/12
Developmental regression (HP:0002376)	NP	three separate 6-month episodes of regression and plateau	–	possible recent regression	regression at age 16 years attributed to worsening anxiety, with new aggressive behaviors	–	–	no regression, but developed personality changes (HP:0000751) and memory problems (HP:0002354) at age 8 years			NP		4/12
Seizures (HP:0001250)	NP	EEG revealed right centroparietal epileptiform discharges	–	generalized tonic-clonic and absence	during childhood, with no discernable seizures since puberty, no longer on anticonvulsants	absence seizures	+	started at 13 years old			2/4		8/12
Intellectual disability (HP:0001249)	NP	+	+	+	+	+	+	mild			1/4		8/12
Autism spectrum disorder (HP:0000729)	NP	+	+	+	–	+	+	–			1/4		6/12
Hypotonia (HP:0001252)	+	+	+	+	+	+	+	–			1/4		8/12
Dystonia (HP:0001332)	NP	–	+	+	–	–	–	hypertonia/spasticity of the right extremities due to hemiplegia (HP:0001276, HP:0004374)			NP		3/12
Neck and back arching in infancy	NP	+	+	–	+	NP	–	–			NP		3/12
Abnormal movements (HP:0100022)	NP	hand flapping	hand flapping, kicking, rubs side of head	head banging	occasional hand flapping	hand flapping	head hitting, stimming arms and legs	–			1/4		7/12
Pica (HP:0011856)	NP	eats hair, paper, feces	NP	frequently puts objects in mouth	NP	NP	chews on hands, toes, clothes, paper, furniture, toys	NP			NP		3/12
Ataxia (HP:0001251)	NP	+	+	+	ataxic high-stepping gait	+	+	ataxic gait			NP		7/12

(Continued on next page)

Table 1. Continued

Individual ID	1	2	3	4	5	6	7 (Hajjes et al. ⁶ individual 15)	8	9	10	11	12	Summary
Difficulty sleeping (HP:0002360)	NP	obstructive sleep apnea prior to removal of tonsils and adenoids; sleeps >12 h and exhibits daytime sleepiness	-	+	woke up 10x per night in childhood, current symptoms are occasional and mild	NP	no sleep study, but reportedly very light sleeper	insomnia, takes clonidine for it			NP		5/12
Musculoskeletal													
Skeletal abnormality (HP:0000924)	NP	-	-	mild pectus excavatum (HP:0000767), hip dysplasia (HP:0001385), sixth lumbar vertebrae (HP:0008416)	short Achilles tendons have caused foot distortion and difficulty walking (HP:0001771)	NP	hip dysplasia (HP:0001385), pes planus (HP:0001763), leg length discrepancy (HP:0100559)	contractures on right side (HP:0001371), two Achilles tendon release surgeries (HP:0001771)			1/4		5/12
Scoliosis (HP:0002650)	NP	-	-	-	-	neurogenic	-	-			NP		1/12
Joint hypermobility (HP:0001382)	NP	+	+	+	-	hyperextensible elbows and knees	+	-			1/4		6/12
GI system													
Failure to thrive (HP:0001508)/feeding difficulty (HP:0011968)	+	+	-	poor weight gain but normal linear growth	+	-	+	-			2/4		7/12
Uses gastrostomy tube	NP	planned but not yet inserted	-	inserted at 9 years old	-		inserted at 5 years old	-			NP		3/12
GI reflux (HP:0002020)	NP	+	-	+	+	-	-	+			1/4		5/12
Constipation (HP:0002019)/diarrhea (HP:0002014)	NP	constipation	constipation	constipation	-	-	constipation and diarrhea	-			diarrhea 1/4		5/12
Other													
Urogenital system (HP:0000119)	NP	incontinence	incontinence	neurogenic bladder; incontinence; swollen left kidney after birth; small scrotum, retractile testes	toilet trained at age 6 years, still some incontinence	NP	incontinence	history of several urinary tract infections (HP:0000010)			kidney abnormality 1/4		7/12
Skin abnormality (HP:0000951)	NP	easy scarring, keratosis pilaris	-	easy scarring	easy scarring	-	keratosis pilaris, facial flushing	-			unspecified abnormality 1/4		5/12

(Continued on next page)

Table 1. Continued

Individual ID	1	2	3	4	5	6	7 (Hajjes et al. ⁶ individual 15)	8	9	10	11	12	Summary
Immune system (HP:0002715)	NP	neutropenia (HP:0001875); granulocytopenia (HP:0001913); high lymphocyte percentage (HP:0100827)	–	intermittent leukocytosis (HP:0001974)	– (no antibiotics needed for >10 years)	NP	–	–	–	unspecified abnormality	1/4		3/12
Fever (HP:0001954)	NP	chronic (HP:0001955)	–	fever of unknown etiology (HP:0001955)	fever of unknown etiology in childhood (HP:0001955)	–	–	–	–	chronic fever	1/4		4/12
Cardiac abnormality (HP:0001627)	dilated cardiomyopathy (HP:0001644)	–	Bicuspid aortic valve (HP:0001647)	Atrial septal defect (HP:0001631), congestive heart failure in infancy (HP:0001635)	–	NP	–	–	–		NP		3/12
Lung abnormality (HP:0002086)	immature lungs (HP:0006703)	recurrent upper respiratory infections (HP:0002788); frequent nebulizer use (budesonide and albuterol)	recurrent upper respiratory infections (HP:0002788); uses inhaler and nebulizer	poor airway clearance requiring vest therapy, suctioning, and cough assist; recurrent upper respiratory infections (HP:0002788)	–	–	recurrent upper respiratory infections (HP:0002788); hospitalized four times for pneumonia, once for bronchiolitis	–	–		NP		5/12
Congenital diaphragmatic hernia (HP:0000776)	NP	–	–	–	–	–	–	–	–		1/4		1/12
Other	NP	hypothyroidism (HP:0000821); tooth misalignment (HP:0000692); consistently elevated BUN/creatinine ratio (HP:0040081), alkaline phosphatase (HP:0004379), and prolactin (HP:0040086)	–	history of angioedema with levetiracetam use (HP:0100665); hemangioma (HP:0001028); 2-vessel umbilical cord (HP:0001195); adverse reaction to therapeutic botulinum toxin; enlarged liver that resolved after birth (HP:0006564); hyponatremia (HP:0002902)	psychosis induced by fluoxetine; agitation with sedatives and general anesthesia	NP	intolerant of wheat and dairy (not allergic); reduced fetal movement (HP:0001558)	–	–		NP		4/12

All variants are considered likely pathogenic. Phenotypes are indicated as either positive, negative, or not phenotyped or reported (NP) for each individual. For research-consented individuals, individual-level phenotypic information is presented. For the four other clinical individuals (individuals 9–12), phenotypic information is presented in aggregate. The summary column indicates how many individuals were positive for a given phenotype. All cDNA variants are based on the NM_000937.4 transcript definition. All genomic coordinates are based on the hg19 genome build. Human Phenotype Ontology (HPO) IDs are indicated for phenotypes where appropriate. +, positive; –, negative; BUN, blood urea nitrogen; het, heterozygous; GI, gastrointestinal; NA, not applicable.

Table 2. Phenotypic analyses of potentially pathogenic *POLR2A* variants in yeast

<i>RPB1</i> alleles	<i>POLR2A</i> (Human)	Individual with variant	YPD 30°C	YPD 37°C	SC-Leu MPA (20µg/ml)	YPD + Formamide (3%)	SC-Lys (Spt ⁻)	YP Raf/Gal	SC-His
WT	WT	NA	+	+	MPA ^R	Formamide ^R	-	Gal ^S	-
Pro24Arg	Pro28Arg	9	-/+	-	MPA ^R	Formamide ^S	-	Gal ^S	-
Glu26Val	Glu30Val	NA	+	+	MPA ^R	Formamide ^R	-	Gal ^S	-
Glu104His	Arg108His	10	+	+/-	MPA ^R	Formamide ^R	-	Gal ^S	-
Glu104Leu	Arg108Leu	NA	+/-	-/+	MPA ^R	Weak Formamide ^S	-	Gal ^S	-
Arg134Trp	Arg140Trp	11	-/+	-	MPA ^R	Formamide ^S	-	Gal ^S	-
Arg175Trp	Arg192Trp	NA	+	+	MPA ^R	Formamide ^R	-	Gal ^S	-
Gln313Cys	Arg327Cys	NA	+	+	MPA ^R	Formamide ^R	-	Gal ^S	-
Leu388Val	Leu402Val	NA	+	+	MPA ^R	Formamide ^R	-	Gal ^S	-
Asp423ΔIle424Δ	Asp437_Leu438del	NA	+	+	MPA ^R	Weak Formamide ^S	-	Gal ^R	-
Asp423Δ	Asp437del	NA	+	+	MPA ^R	Weak Formamide ^S	-	Gal ^R	-
Ile424Δ	Leu438del	1	+	+	MPA ^R	Formamide ^R	-	Gal ^R	-
Ala1069Val	Ala1092Val	12	+	+	MPA ^R	Formamide ^R	-	Gal ^R	-
Thr1272Ala	Thr1297Ala	NA	+	+	MPA ^R	Formamide ^R	-	Gal ^S	-/+
Gly1388Arg	Gly1418Arg	6	+	+	MPA ^R	Formamide ^R	-	Slight Gal ^R	-
Gly1388Val	Gly1418Val	NA	+	+	MPA ^R	Formamide ^R	-	Slight Gal ^R	-

Table summarizing phenotypic analysis of potentially pathogenic *POLR2A* variants in yeast by spot assay (Figure 3). General (growth at standard propagation temperature on standard medium YPD 30°C) or conditional growth defects (YPD 37°C), YPD in presence of 3% formamide (a protein-folding stressor), or minimal media that enable detection of transcription-related phenotypes are shown: addition of drug mycophenolic acid (MPA) detecting defective *IMD2* expression, medium lacking lysine (SC-Lys) for detection of altered transcription due to Suppressor of Ty phenotype (Spt⁻) at the *lys2-128Δ* reporter allele, rich medium YP with 2% raffinose and 1% galactose for detection of altered transcription apparent as suppression of the galactose toxicity (Gal^S) imposed by the *gal10Δ56* reporter allele (YP Raf/Gal), medium lacking histidine for detection of altered transcription allowing constitutive expression of the *imd2Δ::HIS3* transcriptional reporter (SC-His). Shaded cells indicate a phenotype different from WT, with darker shading indicating a stronger phenotype than lighter shading. Strength of growth is indicated as robust growth (+), reduced growth (+/-), weak growth (-/+), severe growth defect (-/-/+), no growth (-).

frameshift variant in the C-terminal domain (CTD), which is likely to escape nonsense-mediated decay as it occurs within the last exon of the gene.¹³

Missense variants

Of the ten individuals harboring missense variants, four non-research-consented individuals have phenotypes reported in aggregate (individuals 9–12) rather than at an individual level. Six of these ten missense variants were confirmed to be inherited *de novo*. The remaining four were observed in clinical samples for which parental ES was not performed, but their pathogenicity is further supported by functional evidence and phenotypic similarity. Commonly reported phenotypes among these individuals include developmental delay (10/10), intellectual disability (7/7), seizures ($\geq 7/10$), hypotonia ($\geq 7/10$), abnormal movements ($\geq 7/10$), ataxia ($\geq 6/10$), autism spectrum disorder (ASD) ($\geq 6/7$), failure to thrive/feeding difficulty ($\geq 6/10$), joint hypermobility ($\geq 6/10$), abnormal brain MRI ($\geq 5/10$), incontinence ($\geq 5/10$), skin abnormalities including keratosis pilaris and easy scarring ($\geq 5/10$), visual impairment ($\geq 4/10$), short stature ($\geq 4/10$), difficulty sleeping ($\geq 4/10$), skeletal abnormalities ($\geq 4/10$), recurrent upper respiratory infections

($\geq 4/10$), and cool distal extremities ($\geq 4/10$). (Diagnoses of intellectual disability and autism spectrum disorder cannot be ruled out for three clinical samples, as phenotyping for these individuals is limited to what was included on the ES requisition, ordered for these individuals at an age too young to typically diagnose intellectual disability or ASD.)

Individuals 4 and 5 are of note, sharing an identical variant with a previously reported individual: c.3752A>G (p.Asn1251Ser; Haijes et al.⁶) Individual 14 was reported as a 6-year-old girl with hypotonia, strabismus, frog position in infancy, decreased endurance, feeding difficulties, recurrent respiratory tract infections, disturbed sleeping, gastro-esophageal reflux, failure to thrive, microcephaly, brachyplagiocephaly, decreased fetal movements, aggressive behavior, pectus excavatum, walking at 5.5 years of age, and mega cisterna magna.⁶ A detailed clinical description of individuals 4 and 5 is included in the supplement of this manuscript (Supplemental note). There is considerable variability in age of walking across these three individuals, reported as 3.5 (individual 5), 4.5 (individual 4), and 5.5 (Haijes et al.,⁶ individual 14) years of age. Other notable phenotypic differences include the presence of a cardiac abnormality




Figure 1. POLR2A allelic series

(A) The x axis represents the entire length of the POLR2A protein, spanning 1,970 amino acids. Potentially pathogenic variants observed in individuals enrolled in this study are shown along the top in blue, with each circle representing an individual harboring the indicated variant. Previously reported pathogenic variants are shown along the bottom, including both those associated with Mendelian (green) and somatic (red) disease. Each variant is mapped to its corresponding structural domain, as indicated by the legend. Previously reported Mendelian variants are limited to those occurring in the Active site, Pore 1, Funnel, Cleft, Trigger Loop, Jaw, and C-terminal domain (CTD). Variants observed in this study additionally include those affecting the Clamp core, Clamp head, and Dock. Variant p.Asn1251Ser is the only variant recurrently reported to date and is observed in three unrelated individuals. Variant p.His439_Leu440del is the only variant reported in both somatic (meningioma) and Mendelian (*POLR2A*-related congenital transcriptopathy) disorders.


(B) Structural view of yeast Pol II (amalgam of RNA polymerase and TFIIS from PDB 1Y1V and nucleic acid DNA and RNA components from PDF 2E2H). Non-Rpb1 (POLR2A ortholog) subunits are shown in transparent surface view. Rpb1 is shown as cartoon within transparent surface. Domains of Rpb1 are color coded to match diagram in (A), and implicated residues are labeled and shown as colored spheres. On left is an oblique “front” view of the Pol II complex; on right, the structure is rotated to a “top” view. Generally speaking, pathogenic variants are widely distributed throughout the structure, without any obvious patterns of clustering, potentially consistent with multiple, distinct mechanisms of pathogenicity.

(atrial septal defect) in individual 4 and the presence of recurrent respiratory infections in individual 4 and Haijes et al.⁶ individual 14, but not in individual 5. Facial dysmorphism is relatively similar for individuals 4 and 5 (Figure 2).

Other variants

We report one frameshift variant that is potentially pathogenic—g.7417023_7417024del (GenBank: NC_000017.10) (c.5440_5441del [NM_000937.4]; p.Gln1814Valfs99ter)—observed in individual 8, with a remarkably


Ind. 2 | p.Ser1094Phe



Ind. 3 | p.Thr1136Ile




Ind. 4 | p.Asn1251Ser



Ind. 5 | p.Asn1251Ser



Ind. 7 | p.Arg1603His



Composite – 14 cases




Figure 2. Photographs of individuals with putatively pathogenic *POLR2A* variants

All research subjects consenting to publication of photographs are included. High forehead, mild downslanting palpebral fissures, and strabismus are observed in individual 2. High forehead, epicanthus, downslanting palpebral fissures, tented mouth, and simplified and prominent ears are observed in individual 3. Prominent supraorbital ridges, high posterior hairline, upslanted palpebral fissures, large, fleshy ears, deep-set eyes, and high palate are observed in individual 4; individual 5, affected by the same variant as individual 4, exhibits remarkable similarity to individual 4, with broad forehead, bilateral epicanthus, prominent supraorbital ridges, and deep-set eyes. Prominent ears, thin upper lip, tubular nose, and smooth philtrum are observed in individual 7. In the lower-right panel, a composite image was created using the Face2Gene tool, compiled using the five individuals reported here together with photos of individuals previously reported by Haijes et al.⁶ All photos published by Haijes et al. were included except for two photos with individuals wearing glasses (Haijes et al. individuals 7 and 13) and an additional photo (Haijes et al. individual 2) unable to be processed by Face2Gene, likely due to poor lighting. The composite image reveals no consistent, remarkably distinctive facial dysmorphism observed across all individuals affected by potentially pathogenic variants in *POLR2A*.

more mild presentation than the individuals affected by missense variants. This variant occurs in the last exon of the gene (29/29) and leads to a premature termination near the C-terminal end of the protein, after amino acid residue 1912/1970, and an alteration of 99 amino acids. This alteration would result in truncation of the CTD by 20 heptapeptide repeats and 1 partial out of 52. Truncation of CTD repeats can confer phenotypes in model organisms.^{14–20} Furthermore, given its position in the gene, it is predicted to escape nonsense-mediated decay, with a fully expressed, yet truncated, protein product. Individual 8 presented at 8 years of age with hypertonia/spasticity of the right extremities, recent worsening headache, memory problems and personality changes, hemiplegia, and delayed speech and motor milestones. MRI of the brain revealed left hippocampal atrophy, and an electroencephalogram (EEG) revealed a focus of spike activity in the left central region. Clinical ES initially failed to detect any pathogenic variants consistent with phenotypic presentation. At most recent follow-up, individual 8 was reported to have developed seizures at age 13 years, recurrent urinary tract infections, and a history of two Achilles tendon release surgeries. Daily severe headaches were reported, as well as difficulty sleeping. Aggregate genocentric reanalysis through HARLEE⁷ revealed individual 8 as positive for the ultra-rare C-terminal frameshift variant in *POLR2A*. Sanger sequencing of proband and maternal saliva samples revealed the variant to be maternally inherited. The mother of individual 8 reports no significant related medical history other than delayed speech and mild learning difficulty. Maternal family history is also positive for a son who was born at 35 weeks and had hypoplastic left heart, brain anomaly, and failure to thrive. He had three open heart surgeries and died at 7 months of age. He was reported to have a chromosome 6p duplication with an unknown *POLR2A* genotype.

Harboring an in-frame deletion of two amino acids, individual 1 presented with the most severe phenotype of all evaluated individuals. Clinical ES was ordered at 3 months of age, with reported phenotypes of immature lungs, dilated cardiomyopathy, failure to thrive, hypotonia, developmental delay, dysmorphic features, and abnormal brain MRI findings including polymicrogyria, ventriculomegaly, hydrocephalus, and hypomyelination. ES failed to detect any known pathogenic variants consistent with phenotypic presentation. Individual 1 reportedly died during infancy. As above, genocentric reanalysis identified an ultra-rare variant in *POLR2A*—chr17:g.7401503GACCTTC>G (NM_000937.4) (c.1314_1319del; p.His439_Leu440del). The average GERP score across the six deleted nucleotides is 4.64, indicative of high evolutionary conservation. Notably, this same variant, when present as a developmental somatic mutation, has been established as causal for a subset of meningiomas.⁵ Meningioma was not reported in individual 1. Sanger sequencing of parental saliva samples failed to detect the variant. Sanger sequencing in individual 1 confirmed the presence of the heterozygous variant.

Functional studies

Functional assays were conducted in yeast to further evaluate the pathogenicity of observed *POLR2A* variants in clinical and research samples (Figure 3). As noted above, the large subunit of Pol II (encoded by *POLR2A* in human, *RPB1* in yeast) is highly conserved in sequence and structure. We previously established a number of plate phenotypes highly predictive of transcription defects due to specific alterations to Pol II catalytic activity in yeast.^{21,22} Residues analogous to some identified in individuals had been identified previously as being mutated in genetic screens for yeast transcription mutants; *rpb1* Pro24Ser was identified as *rpb1-9*¹⁵ (analogous residue to *POLR2A* p.Pro28), while *rpb1* Gly1388Val was identified as *sua8-4*²³ (analogous to *POLR2A* p.Gly1418). Here we employed these tests to interrogate conserved residues impacted by missense variants observed in humans for growth defects in yeast. The yeast strains utilized were the same as in Haijes et al.,⁶ as their strains were derived from the Kaplan lab. Mutant plasmids encoding variants in conserved residues identified in a subset of individuals were introduced into yeast as the sole copy of *RPB1* and phenotyped on a number of growth media. We observed conditional growth defects as well as phenotypes related to altered transcription for a subset of mutants (Table 2). Conditional defects such as temperature sensitivity or formamide sensitivity are consistent with protein folding or assembly defects exacerbated by heat or solvent, and these were observed for yeast *rpb1* Pro24Arg, Glu104Leu, and Arg134Trp (analogous to p.Pro28Arg, p.Arg108Leu, and p.Arg140Trp, respectively). Other subsets of alleles show suppression of the *gal10Δ56* transcriptional reporter (Asp423delIle424Δ, Asp423Δ, Ile424Δ, Asp1069Val, Gly1388Arg, and Gly1388Val) or constitutive expression of the *imd2promoter::HIS3* transcriptional reporter due to altered transcription start selection (Thr1272Ala) (see Table 2 for corresponding human variants).^{21,22,24} Each of these phenotypes has been linked to altered Pol II transcription, usually due to decrease in Pol II catalytic function.^{21,22,24,25} These phenotypic effects are relatively minor and would be consistent with subtle alterations to Pol II function.

Discussion

Herein, we confirm the recent discovery of association between pathogenic germline variation in *POLR2A* and a phenotypically heterogeneous neurodevelopmental disorder.⁶ We report the transmission of a potentially pathogenic *POLR2A* variant within a family—individual 8, inheriting a p.Gln1814Valfs99ter variant from a mother with a remarkably mild presentation of delayed speech and mild learning difficulties. We observe several previously unreported phenotypes (as compared to Haijes et al.⁶) in individuals with *POLR2A*-related disorders, including ataxia (observed in 7/12, or 58.3% of individuals), joint hypermobility (6/12, 50%), short stature

(5/12, 41.7%), skin abnormalities including easy scarring and keratosis pilaris (5/12, 41.7%), recurrent febrile illness of unknown etiology (4/12, 33.3%), congenital cardiac abnormalities (3/12, 25%), immune system abnormalities (3/12, 25%), hip dysplasia (2/12, 16.7%), and short Achilles tendons (2/12, 16.7%). We also report a significantly higher proportion of individuals with epilepsy (8/12, 66.7%) than previously reported (3/15, 20%) (p value = 0.014196; chi-square test) and a somewhat lower proportion of individuals with hypotonia (8/12, 66.7%) than previously reported (14/15, 93.3%) (p value = 0.076309).⁶ We describe the facial dysmorphology of a subset of affected individuals, which is generally mild and nonspecific across individuals with different variants but remarkably similar for the two reported individuals sharing the same variant (individuals 4-5) (Figure 2).

In this cohort, previously unreported neuroradiological anomalies include polymicrogyria (2/12, 16.7%) and various benign, congenital anomalies, which cannot yet be ruled out as unrelated to *POLR2A* dysfunction, each occurring in a single individual: Rathke cleft cyst, hemangioma, and a small, enhancing developmental venous anomaly (DVA). We also report one individual (individual 1) with a germline variant identical to a previously reported meningioma-causing somatic mutation (p.His439_Leu440del).⁵ As individual 1 died during infancy, the extent of correlation between germline inheritance of p.His439_Leu440del (or other pathogenic germline variants) and risk of developing meningioma remains unclear.

Due to the centrality of *POLR2A* in transcriptional networks and the wide range of ways in which its function is known to be regulated, it can be reasonably inferred that a spectrum of possible pathogenic genetic variants will present with differential phenotypic presentation and severity. Future efforts should focus on elucidating the molecular mechanisms of pathogenicity—common or distinct—across the spectrum of known pathogenic *POLR2A* variants. Phenotypes of tested mutants in yeast in most instances were relatively weak, though a subset are strongly predicted to have protein structural or stability defects. Known catalytic mutants identified in yeast cause widespread transcriptional defects when introduced into human cells and likely would not be viable in an organism.^{26–28} For example, a known slow-elongating variant has been introduced into mouse embryonic stem cells (Polr2a Arg749His, analogous to Arg726His in yeast), could not be transmitted through the germline, and caused early embryonic lethality.²⁹ Mouse embryonic stem cells containing Arg749His showed defects upon neuronal differentiation, likely deriving from observed altered elongation rate, gene expression, and alternative splicing changes. Of interest, long genes, which are enriched among neuronally expressed genes, might be predicted to be especially sensitive to altered Pol II elongation or cotranscriptional splicing defects.³⁰ Haijes et al.⁶ delineate two potential molecular mechanisms of disease:




Figure 3. Phenotypes of yeast *rpb1* mutants analogous to human *POLR2A* alleles

10-fold serial dilution of saturated cultures of *rpb1* mutants or *RPB1* wild-type (WT) control were spotted onto different media and phenotypes determined. Growth on YPD, a rich medium containing dextrose as carbon source, serves as control, against which growth phenotypes on YPD at 37°C and 3% formamide are compared. Growth sensitivity to 20 µg/mL of the drug mycophenolic acid (MPA) added to a synthetic defined medium lacking leucine (SC-Leu) is compared to growth on SC-Leu. SC-Leu serves as a selection medium for *LEU2* expressing plasmids. The presence of *gal10Δ56* in cells confers galactose toxicity that can be suppressed by mutants that alter transcription and is apparent as resistance to galactose, as evidenced by comparing YPRaf/Gal (containing galactose and raffinose as carbon source) to YPRaf (containing only raffinose). Growth of cells possessing the *lys2-128Δ* on SC-Lys results in Lys⁺/Spt⁻ phenotype, wherein WT cells are Lys⁻; this medium can detect a subset of Pol II alleles with increased catalytic activity. In cells containing *imd2Δ::HIS3*, aberrant constitutive expression from the *IMD2* promoter can be detected by growth on medium lacking histidine, as this allele replaces the *IMD2* open reading frame with *HIS3*, meaning *HIS3* is now under control of the *IMD2* promoter; mutants defective for Pol II catalytic activity can confer this phenotype. Strains possessing *imd2Δ::HIS3* have been derived from CKY865, whereas all the other mutants have been tested in CKY283 (Table S1). For all assays and mutants (Table S2), serial dilutions demonstrating abnormal phenotypes as compared to WT are indicated with a black box.

haploinsufficiency (with a relatively mild presentation) and a dominant-negative effect caused by aberrant Pol II elongation. We emphasize that despite the relatively mild presentation of all individuals harboring truncating and frameshift variants reported to date (p.Gln700*, p.Gln735*, p.Pro1767fs, and p.Gln1814fs),⁶ the poten-

tially pathogenic CTD frameshift variants (p.Pro1767fs and p.Gln1814fs) most likely escape nonsense-mediated decay and thus exhibit a dominant-negative mechanism of pathogenicity. Therefore, while haploinsufficiency associated with p.Gln700* and p.Gln735* almost certainly constitutes a distinct mechanism of pathogenicity,

expressed mutant *POLR2A* products can cause the full range of phenotypic severity observed in *POLR2A*-related disorders. Taken together, these molecular and phenotypic data suggest that these pathogenic variants constitute a spectrum of transcriptional dysfunction, with phenotypes likely explained by a combination of specific *POLR2A* variation in conjunction with the genetic burden across a potential variant- or domain-specific network of interacting partners. Such a model could explain both a degree of phenotypic convergence (i.e., similar facial dysmorphism in individuals 4 and 5) and variable expressivity (i.e., microcephaly, cardiac and immune abnormalities present in individual 4 but not in individual 5) or incomplete penetrance (i.e., the mother of individual 8 exhibiting only sub-clinical phenotypes) for a given disease-associated variant. To assess this model, global transcriptional profiling (via RNA-sequencing [RNA-seq], GRO-seq, etc.) could be evaluated across biologically relevant cell types or tissues using patient-derived induced pluripotent stem cell (iPSC) lines. The function of individual pathogenic variants—in the appropriate genetic background—could be assessed by transcriptional profile comparison of patient-derived cells against a split of the same cell line with a mutationally induced wild-type *POLR2A*. The function of different pathogenic variants could then be compared by normalizing their impact against their respective isogenic controls.

Data and Code Availability

POLR2A variants are available on ClinVar: SUB7404119, accession pending review.

Supplemental Information

Supplemental Information can be found online at <https://doi.org/10.1016/j.xhgg.2020.100014>.

Acknowledgments

This work was supported in part by grants UM1 HG008898 from the National Human Genome Research Institute (NHGRI) to the Baylor College of Medicine Center for Common Disease Genetics and UM1 HG006542 from the National Heart, Lung, and Blood Institute (NHLBI) and NHGRI to the Baylor Hopkins Center for Mendelian Genomics. C.D.K. was supported by grants R01 GM097260 and R01 GM120450 National Institute of General Medical Sciences (NIGMS). A.W.H. was supported in part by NIH T32 GM08307-26, The Cullen Foundation, and the Baylor College of Medicine President's Circle. D.P. was supported by Clinical Research Training Scholarship in Neuromuscular Disease partnered by the American Academy of Neurology (AAN), American Brain Foundation (ABF) and Muscle Study Group (MSG), and the International Rett Syndrome Foundation (IRSF grant #3701-1). S.M.W. is supported by the Victorian Government's Operational Infrastructure Support Program. S.D. was supported by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung, and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research

Institute grant R01 HG009141. We thank Ali Jalali and Amy L. McGuire for the valuable discussions. Last, we thank the individuals participating in research and their families for their assistance and significant contributions to this research.

Declaration of interests

J.R.L. has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals, and is a co-inventor on multiple US and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from clinical genetic testing offered in the Baylor Genetics Laboratory.

Received: September 5, 2020

Accepted: November 6, 2020

Web resources

Baylor Genetics Laboratory, <https://baylorgenetics.com>
ClinVar, <https://www.ncbi.nlm.nih.gov/clinvar/>
Face2Gene tool, <https://www.face2gene.com>
OMIM, <https://www.omim.org>
The Human Phenotype Ontology, <https://hpo.jax.org/app/>

References

1. Jeronimo, C., Collin, P., and Robert, F. (2016). The RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain. *J. Mol. Biol.* *428*, 2607–2622.
2. Harlen, K.M., and Churchman, L.S. (2017). The code and beyond: transcription regulation by the RNA polymerase II carboxy-terminal domain. *Nat. Rev. Mol. Cell Biol.* *18*, 263–273.
3. Cramer, P., Bushnell, D.A., and Kornberg, R.D. (2001). Structural basis of transcription: RNA polymerase II at 2.8 Å resolution. *Science* *292*, 1863–1876.
4. Cramer, P. (2019). Organization and regulation of gene transcription. *Nature* *573*, 45–54.
5. Clark, V.E., Harman, A.S., Bai, H., Youngblood, M.W., Lee, T.I., Baranoski, J.F., Ercan-Sencicek, A.G., Abraham, B.J., Weintraub, A.S., Hnisz, D., et al. (2016). Recurrent somatic mutations in *POLR2A* define a distinct subset of meningiomas. *Nat. Genet.* *48*, 1253–1259.
6. Haijes, H.A., Koster, M.J.E., Rehmann, H., Li, D., Hakonarson, H., Cappuccio, G., Hancarova, M., Lehalle, D., Reardon, W., Schaefer, G.B., et al. (2019). De Novo Heterozygous *POLR2A* Variants Cause a Neurodevelopmental Syndrome with Profound Infantile-Onset Hypotonia. *Am. J. Hum. Genet.* *105*, 283–301.
7. Hansen, A.W., Murugan, M., Li, H., Khayat, M.M., Wang, L., Rosenfeld, J., Andrews, B.K., Jhangiani, S.N., Coban Akdemir, Z.H., Sedlazeck, F.J., et al.; Task Force for Neonatal Genomics (2019). A Genocentric Approach to Discovery of Mendelian Disorders. *Am. J. Hum. Genet.* *105*, 974–986.
8. Traynelis, J., Silk, M., Wang, Q., Berkovic, S.F., Liu, L., Ascher, D.B., Balding, D.J., and Petrovski, S. (2017). Optimizing genomic medicine in epilepsy through a gene-customized

- approach to missense variant interpretation. *Genome Res.* 27, 1715–1729.
9. Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., O'Donnell-Luria, A.H., Ware, J.S., Hill, A.J., Cummings, B.B., et al.; Exome Aggregation Consortium (2016). Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 536, 285–291.
 10. Davydov, E.V., Goode, D.L., Sirota, M., Cooper, G.M., Sidow, A., and Batzoglou, S. (2010). Identifying a high fraction of the human genome to be under selective constraint using GERP++. *PLoS Comput. Biol.* 6, e1001025.
 11. Kent, W.J., Sugnet, C.W., Furey, T.S., Roskin, K.M., Pringle, T.H., Zahler, A.M., and Haussler, D. (2002). The human genome browser at UCSC. *Genome Res.* 12, 996–1006.
 12. Katoh, K., Misawa, K., Kuma, K., and Miyata, T. (2002). MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Res.* 30, 3059–3066.
 13. Coban-Akdemir, Z., White, J.J., Song, X., Jhangiani, S.N., Fatih, J.M., Gambin, T., Bayram, Y., Chinn, I.K., Karaca, E., Punetha, J., et al.; Baylor-Hopkins Center for Mendelian Genomics (2018). Identifying Genes Whose Mutant Transcripts Cause Dominant Disease Traits by Potential Gain-of-Function Alleles. *Am. J. Hum. Genet.* 103, 171–187.
 14. Nonet, M., Sweetser, D., and Young, R.A. (1987). Functional redundancy and structural polymorphism in the large subunit of RNA polymerase II. *Cell* 50, 909–915.
 15. Bartolomei, M.S., Halden, N.F., Cullen, C.R., and Corden, J.L. (1988). Genetic analysis of the repetitive carboxyl-terminal domain of the largest subunit of mouse RNA polymerase II. *Mol. Cell. Biol.* 8, 330–339.
 16. Scafe, C., Martin, C., Nonet, M., Podos, S., Okamura, S., and Young, R.A. (1990). Conditional mutations occur predominantly in highly conserved residues of RNA polymerase II subunits. *Mol. Cell. Biol.* 10, 1270–1275.
 17. Meisels, E., Gileadi, O., and Corden, J.L. (1995). Partial truncation of the yeast RNA polymerase II carboxyl-terminal domain preferentially reduces expression of glycolytic genes. *J. Biol. Chem.* 270, 31255–31261.
 18. Litingtung, Y., Lawler, A.M., Sebald, S.M., Lee, E., Gearhart, J.D., Westphal, H., and Corden, J.L. (1999). Growth retardation and neonatal lethality in mice with a homozygous deletion in the C-terminal domain of RNA polymerase II. *Mol. Gen. Genet.* 261, 100–105.
 19. Chapman, R.D., Conrad, M., and Eick, D. (2005). Role of the mammalian RNA polymerase II C-terminal domain (CTD) nonconsensus repeats in CTD stability and cell proliferation. *Mol. Cell. Biol.* 25, 7665–7674.
 20. Gibbs, E.B., Lu, F., Portz, B., Fisher, M.J., Medellin, B.P., Laremore, T.N., Zhang, Y.J., Gilmour, D.S., and Showalter, S.A. (2017). Phosphorylation induces sequence-specific conformational switches in the RNA polymerase II C-terminal domain. *Nat. Commun.* 8, 15233.
 21. Kaplan, C.D., Jin, H., Zhang, I.L., and Belyanin, A. (2012). Dissection of Pol II trigger loop function and Pol II activity-dependent control of start site selection in vivo. *PLoS Genet.* 8, e1002627.
 22. Malik, I., Qiu, C., Snavely, T., and Kaplan, C.D. (2017). Wide-ranging and unexpected consequences of altered Pol II catalytic activity in vivo. *Nucleic Acids Res.* 45, 4431–4451.
 23. Berroteran, R.W., Ware, D.E., and Hampsey, M. (1994). The *sua8* suppressors of *Saccharomyces cerevisiae* encode replacements of conserved residues within the largest subunit of RNA polymerase II and affect transcription start site selection similarly to *sua7* (TFIIB) mutations. *Mol. Cell. Biol.* 14, 226–237.
 24. Kaplan, C.D. (2013). Basic mechanisms of RNA polymerase II activity and alteration of gene expression in *Saccharomyces cerevisiae*. *Biochim. Biophys. Acta* 1829, 39–54.
 25. Qiu, C., Jin, H., Vvedenskaya, I., Llenas, J.A., Zhao, T., Malik, I., Visbisky, A.M., Schwartz, S.L., Cui, P., Čabart, P., et al. (2020). Universal promoter scanning by Pol II during transcription initiation in *Saccharomyces cerevisiae*. *Genome Biol.* 21, 132.
 26. Fong, N., Saldi, T., Sheridan, R.M., Cortazar, M.A., and Bentley, D.L. (2017). RNA Pol II Dynamics Modulate Co-transcriptional Chromatin Modification, CTD Phosphorylation, and Transcriptional Direction. *Mol. Cell* 66, 546–557.e3.
 27. Fong, N., Kim, H., Zhou, Y., Ji, X., Qiu, J., Saldi, T., Diener, K., Jones, K., Fu, X.D., and Bentley, D.L. (2014). Pre-mRNA splicing is facilitated by an optimal RNA polymerase II elongation rate. *Genes Dev.* 28, 2663–2676.
 28. Saldi, T., Fong, N., and Bentley, D.L. (2018). Transcription elongation rate affects nascent histone pre-mRNA folding and 3' end processing. *Genes Dev.* 32, 297–308.
 29. Maslon, M.M., Braunschweig, U., Aitken, S., Mann, A.R., Kilanowski, F., Hunter, C.J., Blencowe, B.J., Kornblihtt, A.R., Adams, I.R., and Cáceres, J.F. (2019). A slow transcription rate causes embryonic lethality and perturbs kinetic coupling of neuronal genes. *EMBO J.* 38, e101244.
 30. Zylka, M.J., Simon, J.M., and Philpot, B.D. (2015). Gene length matters in neurons. *Neuron* 86, 353–355.

Supplemental Information

**Germline mutation in *POLR2A*: a heterogeneous,
multi-systemic developmental disorder characterized
by transcriptional dysregulation**

Adam W. Hansen, Payal Arora, Michael M. Khayat, Leah J. Smith, Andrea M. Lewis, Linda Z. Rossetti, Joy Jayaseelan, Ingrid Cristian, Devon Haynes, Stephanie DiTroia, Naomi Meeks, Mauricio R. Delgado, Jill A. Rosenfeld, Lynn Pais, Susan M. White, Qingchang Meng, Davut Pehlivan, Pengfei Liu, Marie-Claude Gingras, Michael F. Wangler, Donna M. Muzny, James R. Lupski, Craig D. Kaplan, and Richard A. Gibbs

Supplemental Note: Case Reports

Individual 4

Individual 4 presented as a ten-year-old boy who was originally seen in the genetics clinic for global developmental delay, seizure disorder, and spastic cerebral palsy (CP). His parents first became concerned prenatally when he was found to have a two-vessel umbilical cord. He was noted to have an enlarged liver at birth, but that self-resolved. He was also noted to have a heart murmur and was found to have an atrial septal defect. At a few months old, he started having cyanotic spells and went into congestive heart failure. At 4-6 months old, he was noted to have delays—specifically not cooing and not rolling over. He started therapies around that time but was still very delayed. He crawled at 13 months and started walking at 4.5 years. At 5 years, he started saying "mama" and other sounds. He had his first seizure at 3 years of age and was trialed on multiple different anti-epileptic drugs over the course of three months including phenobarbital and levetiracetam but these were discontinued due to adverse reactions including hyperactivity and angioedema, respectively. He was then seizure free until age nine, when they became intractable without a known trigger; however, he has tremors at baseline as well. His seizure types are generalized tonic-clonic (GTC) and absence. He is hypertonic and was diagnosed with CP. His parents have also reported a decline in his motor skills. He was never very steady on his feet, but now his hips are "tighter" and his coordination is much worse than before. It remains unclear whether he is having true developmental regression, periodic regression marked by temporary phases of reduced function, or if he is limited by muscle/tendon problems. Additionally, the patient has self-injurious behaviors, including biting himself, hitting himself, and grabbing his ears. He also hits other people. Furthermore, he has a history of frequent fevers with increased white blood cell count of unknown etiology. This used to occur to him every 1-2 months and sometimes also following a seizure episode (parents note that he is afebrile prior to seizures starting, so they do not believe they are febrile seizures). He has developed some urinary retention. Parents report that he tested negative for Down syndrome, and methylation analyses for Prader-Willi

and Angelman syndromes were negative. He had trio ES in at age seven which was originally negative. At age eleven, he was admitted to the hospital for weakness of all four extremities—which began proximally and progressed to involve distal musculature—and altered mental status several days after a therapeutic botulinum toxin injection. The etiology of this episode was unclear. While he was hospitalized, the inpatient genetics consult team reviewed him and recommended a re-analysis of his prior ES, which revealed a likely pathogenic variant in *POLR2A*—NC_000017.10:g.7412890A>G, NM_000937.4:c.3752A>G (p.Asn1251Ser).

Individual 5

Individual 5, harboring the same genomic variant as Individual 4, is a 21-year-old woman, one of three children born to healthy unrelated parents. She was born after a pregnancy complicated by maternal hypertension, by normal vaginal delivery, with birth weight 3.5kg, at 39 weeks gestation. She had neonatal apnea that was thought to have possibly been seizure-related and had severe feeding problems and gastro-esophageal reflux. She had marked hypotonia and was a placid baby. Epilepsy was diagnosed at 22 months, and seizure types included febrile seizures, tonic-clonic, myoclonic and absence seizures. She was treated with and responded well to valproate and has had no seizures beyond early childhood. Valproate treatment was ceased at age 18. She had poor sleep and some behavioral traits including hand-flapping and a love of water. Development was severely delayed, and she walked at age 3.5 years. She developed single words in her teens but no further speech and communicates using sign language. She was toilet trained. She was an affectionate person with good eye contact. She had strabismus that resolved. There were no concerns regarding hearing. Around the age of sixteen years, she developed significant behavioral disturbance with some aggressive behavior that has been attributed to anxiety and some regression of skills including incontinence. The behavioral problems have shown some improvement with behavioral management strategies, but moderate to severe anxiety persists. She has some ongoing sleep disturbance. At last review she was not on any medication. Examination at last assessment at age 17 years showed a

height of 159cm (25th centile) and head circumference of 53.5cm (25th centile). She has a fair complexion, deep-set eyes, prominent supra-orbital ridges, marked pes planus and a crouched, ataxic, high-stepping gait. Investigations included SNP array, Angelman methylation testing, *UBE3A* sequencing and MLPA, all of which returned a negative result. Brain MRI at one year of age showed prominent third and lateral ventricles. Her EEG showed an excess of high amplitude slow activity during drowsiness and sleep. Trio exome showed a *de novo* missense variant in *POLR2A* (p.Asn1251Ser).

Supplemental Material

Methods

Phenotyping

Phenotypes for Individuals 1, 6, 8-12 were initially obtained through clinical ES requisitions at BG. Attempts were made to establish contact and research consent with each of the patients. Phenotypes for BG samples consenting to participate in research (protocol H-29697 approved by the institutional review board at Baylor College of Medicine) were updated and expanded via a combination of chart review and self-reported data obtained through conversations and questionnaires. Phenotypes for Individuals 2-5 and Individual 7 were obtained after informed research consent via a combination of chart review and self-reported data obtained through conversations and questionnaires.

Functional Evaluation of Variants in Yeast

One missense variant—p.(Gly1418Arg)—affected the homologous amino acid residue to a known yeast variant—p.Gly1388Val—so it was included in addition to p.Gly1388Arg.¹ As annotated by VEP, the protein consequence for the variant observed in Individual 1 (NC_000017.10:g.7401508_7401513del, VCF description hg19:17:7401503:GACCTTC:G) was originally reported as p.(Asp437_Leu438del). After the completion of the yeast experiments, a reexamination of the human genomic data revealed an apparent VEP annotation error, as the true protein consequence of the genetic variant is p.(His439_Leu440del) (equivalent to the meningioma-causing p.Leu438_His439del described by Clark et al).² Therefore, the yeast variants corresponding to p.(Asp437_Leu438del)—including Asp423del and Ile424del—were studied in lieu of those corresponding to p.(Leu438_His439del) or p.(His439_Leu440del). Thus, fifteen variants were studied in addition to the wild type allele.

Yeast strains used in this study were derived from S288C (**Table S1**).³ Phenotyping assays for *rpb1* (yeast homolog of *POLR2A*) mutants were performed on standard media as described by Amberg et al., 2005, with previously noted modifications.^{4,5} Mutations in *RPB1* were generated by site directed mutagenesis using the QuikChange strategy (Stratagene/Agilent) in a pBS KS+ plasmid, followed by transfer into pRS315-based *RPB1* expression vector (expressed from native promoter). Mutant plasmids were transformed by methodology described by Gietz and Woods⁶ into each of two yeast strains in **Table S1**, with plasmid shuffling performed as previously described^{4,7} to remove the wild type (WT) copy of *RPB1* present on a *URA3* plasmid (**Table S2**). Phenotypes were determined by spotting 10-fold serial dilutions of saturated yeast cultures on control or experimental media, as previously described.⁴ General growth was determined in strains derived from CKY283 on rich medium YPD (1% yeast extract, 2% peptone, 2% dextrose w/v) at 30°C or synthetic complete lacking leucine (SC-Leu) at 30°C. Conditional phenotypes were determined on the following media: YPD incubated at 37°C (temperature sensitive Ts- phenotype); YPD supplemented with 3% formamide;⁸ synthetic complete lacking lysine (SC-Lys) for determination of suppression of *lys2-128 θ* (Spt phenotype derived from altered transcription at *lys2-128 θ*);⁹ SC-Leu supplemented with 20 μ g/ml mycophenolic acid (MPA) (detects initiation defects at the *IMD2* gene);¹⁰⁻¹² and YP supplemented with 2% raffinose, 1% galactose and 1 μ g/ml antimycin A (YPRaf/Gal), for determination of suppression of *gal10 Δ 56*. *gal10 Δ 56* confers galactose sensitivity due to altered termination at *GAL10* causing transcription interference at downstream *GAL7*. Suppression of these defects in certain transcription mutants, including Pol II, confers resistance to galactose for *gal10 Δ 56* strains.¹³⁻¹⁵ Constitutive induction of *IMD2*, which can be caused by decreased Pol II initiation efficiency or decreased catalytic activity allowing a normally inducible TSS to be used all the time, was assayed in strains derived from CKY865, containing an *imd2 Δ ::HIS3* reporter.^{4,12} Here, observation of a His⁺ phenotype would indicate abnormal, constitutive transcription from the *IMD2* promoter, which drives *HIS3* expression in *imd2 Δ ::HIS3*.

Strain Number	Genotype
CKY283	<i>MATa ura3-52 his3Δ200 leu2Δ1 or Δ0 trp1Δ63 met15Δ0 lys2-128^o gal10Δ56 rpb1Δ::natMX4 RPB3::TAP::KlacTRP1 [pRP112 RPB1 CEN URA3]</i>
CKY865	<i>MATa leu2Δ0 or Δ1 ura3-52 his3Δ200 met15Δ0 trp1Δ63 lys2-128^o RPB3::TAP::KlacTRP1 rpb1Δ::natMX4 imd2Δ::HIS3 [pRS316 RPB1 CEN URA3]</i>

Table S1 – Yeast strains and genotypes used in this study. S288C-derived strains¹³ and their genotypes used in this study for analyzing general and transcription-associated phenotypes of *RPB1* alleles by plasmid shuffling. The *lys2-128^o*⁹ and *gal10Δ56*^{13–15} alleles of *LYS2* and *GAL10-GAL7* respectively allowed testing for Spt⁻ and Gal^S phenotypes in CKY283, whereas the *imd2Δ::HIS3*^{4,12} allele of *IMD2* allowed analyzing the His⁺ phenotype in CKY865.

Mutant	Plasmid number	Plasmid genotype	Reference
<i>RPB1</i> WT (<i>URA3</i>)	pRP112	<i>RPB1 URA3 CEN ARS</i>	PMID: 3304659
<i>RPB1</i> WT (<i>URA3</i>)	pCK518	pRS316 <i>RPB1 URA3 CEN ARS amp^r</i>	PMID: 22511879 PMID: 23932120
<i>RPB1</i> WT (<i>LEU2</i>)	pCK859	pRS315 <i>RPB1 LEU2 CEN ARS amp^r</i>	PMID: 22511879 PMID: 23932120
Empty Vector	pRS315	pRS315 <i>LEU2 CEN ARS amp^r</i>	PMID: 2659436
<i>rpb1</i> Pro24Arg	pCK2742	pRS315 <i>rpb1</i> P24R <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Glu26Val	pCK2656	pRS315 <i>rpb1</i> E26V <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Glu104His	pCK2658	pRS315 <i>rpb1</i> E104H <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Glu104Leu	pCK2657	pRS315 <i>rpb1</i> E104L <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Arg134Trp	pCK2659	pRS315 <i>rpb1</i> R134W <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Arg175Trp	pCK2660	pRS315 <i>rpb1</i> R175W <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Gln313Cys	pCK2661	pRS315 <i>rpb1</i> Q313C <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Leu388Val	pCK2752	pRS315 <i>rpb1</i> L388V <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Asp423delIle424del	pCK2743	pRS315 <i>rpb1</i> D423ΔI424Δ <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Asp423Δ	pCK2744	pRS315 <i>rpb1</i> D423Δ <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Ile424del	pCK2745	pRS315 <i>rpb1</i> I424Δ <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Ala1069Val	pCK2664	pRS315 <i>rpb1</i> A1069V <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Thr1272Ala	pCK2739	pRS315 <i>rpb1</i> T1272A <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Gly1388Arg	pCK2740	pRS315 <i>rpb1</i> G1388R <i>LEU2 CEN ARS amp^r</i>	This study
<i>rpb1</i> Gly1388Val	pCK2741	pRS315 <i>rpb1</i> G1388V <i>LEU2 CEN ARS amp^r</i>	This study

Table S2 – Yeast mutants and plasmid descriptions used in this study. Description of CEN plasmids used in this study for analyzing *RPB1* alleles in yeast, by plasmid shuffling.^{4,7}

Supplemental References

1. Berroteran RW, Ware DE, Hampsey M. The sua8 suppressors of *Saccharomyces cerevisiae* encode replacements of conserved residues within the largest subunit of RNA polymerase II and affect transcription start site selection similarly to sua7 (TFIIB) mutations. *Mol Cell Biol.* 1994;14(1):226-237. doi:10.1128/mcb.14.1.226
2. Clark VE, Harmancı AS, Bai H, et al. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. *Nat Genet.* 2016;48(10):1253-1259. doi:10.1038/ng.3651
3. Winston F, Dollard C, Ricupero-Hovasse SL. Construction of a set of convenient *saccharomyces cerevisiae* strains that are isogenic to S288C. *Yeast.* 1995;11(1):53-55. doi:10.1002/yea.320110107
4. Kaplan CD, Jin H, Zhang IL, Belyanin A. Dissection of Pol II Trigger Loop function and Pol II activity-dependent control of start site selection in vivo. *PLoS Genet.* 2012;8(4). doi:10.1371/journal.pgen.1002627
5. Amberg DC, Burke DJ, Strathern JN. *Methods in Yeast Genetics: A Cold Spring Harbor Laboratory Course Manual, 2005 Edition.*; 2005.
6. Gietz RD, Woods RA. Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. *Methods Enzymol.* 2002;350:87-96. doi:10.1016/S0076-6879(02)50957-5
7. Boeke JD, Trueheart J, Natsoulis G, Fink GR. [10] 5-Fluoroorotic acid as a selective agent in yeast molecular genetics. *Methods Enzymol.* 1987;154(C):164-175. doi:10.1016/0076-6879(87)54076-9
8. Hampsey M. A Review of Phenotypes in *Saccharomyces Cerevisiae*. *Yeast.* 1997;13(12). doi:10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.0.CO;2-7
9. Simchen G, Winston F, Styles CA, Fink GR. Ty-mediated gene expression of the LYS2 and HIS4 genes of *Saccharomyces cerevisiae* is controlled by the same SPT genes. *Proc Natl Acad Sci U S A.* 1984;81(8 I):2431-2434. doi:10.1073/pnas.81.8.2431

10. Jenks MH, O'Rourke TW, Reines D. Properties of an Intergenic Terminator and Start Site Switch That Regulate IMD2 Transcription in Yeast. *Mol Cell Biol.* 2008;28(12):3883-3893. doi:10.1128/mcb.00380-08
11. Kuehner JN, Brow DA. Regulation of a Eukaryotic Gene by GTP-Dependent Start Site Selection and Transcription Attenuation. *Mol Cell.* 2008;31(2):201-211. doi:10.1016/j.molcel.2008.05.018
12. Malik I, Qiu C, Snavely T, Kaplan CD. Wide-ranging and unexpected consequences of altered Pol II catalytic activity in vivo. *Nucleic Acids Res.* 2017;45(8):4431-4451. doi:10.1093/nar/gkx037
13. Greger IH, Proudfoot NJ. Poly(A) signals control both transcriptional termination and initiation between the tandem GAL10 and GAL7 genes of *Saccharomyces cerevisiae*. *EMBO J.* 1998;17(16):4771-4779. doi:10.1093/emboj/17.16.4771
14. Greger IH, Aranda A, Proudfoot N. Balancing transcriptional interference and initiation on the GAL7 promoter of *Saccharomyces cerevisiae*. *Proc Natl Acad Sci U S A.* 2000;97(15):8415-8420. doi:10.1073/pnas.140217697
15. Kaplan CD, Holland MJ, Winston F. Interaction between transcription elongation factors and mRNA 3'-end formation at the *Saccharomyces cerevisiae* GAL10-GAL7 locus. *J Biol Chem.* 2005;280(2):913-922. doi:10.1074/jbc.M411108200